CT-G32 (SCO-940) from Scohia and Celltrion targets GLP-1, GIP, glucagon and amylin receptors. What the November 2026 preclinical disclosures say, what they leave out, and how far it is from human data.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
The Short Answer
CT-G32, also called SCO-940, is a preclinical drug candidate. Its developers describe it as a "quadruple agonist" designed to act on four hormone receptors involved in appetite and metabolism: GLP-1, GIP, glucagon and amylin.
Scohia Pharma (Japan) identified it through a collaboration with Celltrion that began in 2024. Scohia led discovery and preclinical work; Celltrion is responsible for clinical development, regulatory work, manufacturing and commercialization. No human has received it yet. Celltrion's stated plan is to file an Investigational New Drug (IND) application with US FDA by February 2027, with first patient dosing targeted for the following second quarter.
Everything known about CT-G32 comes from the sponsors. It's worth following, but there is nothing yet to evaluate for use, dosing or safety in people.
Naming note: CT632 (ct632.com) is a separate research-library site. It is not related to the CT-G32 molecule, even though the names look alike in print.
Why Four Receptors?
Each generation of incretin medicines has added a receptor:
Generation
Receptors
Example
Status
Single
GLP-1
Semaglutide
Approved
Dual
GLP-1 + GIP
Tirzepatide
Approved
Triple
GLP-1 + GIP + glucagon
Retatrutide, UBT251
In trials
Combination
GLP-1 + amylin (two molecules)
CagriSema
In trials
Quadruple
GLP-1 + GIP + glucagon + amylin (one molecule)
CT-G32 / SCO-940
Preclinical
Amylin is a hormone released with insulin that adds a separate fullness signal. It's the reason for the interest in combinations like CagriSema and in amylin analogues like eloralintide. CT-G32's pitch is to combine amylin with a retatrutide-like triple profile in a single molecule.
More receptors doesn't automatically mean a better drug. Every receptor added makes tuning harder. Relative strength at each receptor, side effects and how long the drug lasts in the body all have to be balanced. Only human trials can show whether that balance works.
What the Sponsors Disclosed in November 2026
At TIDES Europe (Amsterdam, 3–5 November 2026), Scohia presented preclinical data. According to Scohia's 4 November release:
Receptor activity was shown in lab assays at each of the four receptors.
In diet-induced obese rats, CT-G32 produced "numerically greater weight loss at the same molar dose compared with retatrutide."
In the same rats, a "relatively smaller proportion of lean body mass loss" was reported during weight reduction.
It "improved hyperinsulinemia" (high insulin levels) linked to obesity in the model.
In non-human primates, it showed "prolonged systemic exposure," which the sponsor says suggests potential for a once-weekly formulation.
What wasn't disclosed
The release gives no percentages, doses, group sizes, study durations, error bars or statistics. "Numerically greater" in a press release doesn't mean the difference was statistically meaningful.
Scohia's discovery history credits its peptide-engineering work, so CT-G32 is very likely a peptide. The releases we read don't spell out its structure.
How to Read a Preclinical Headline
Drug development is a ladder. Each rung removes some uncertainty:
Lab and animal studies. CT-G32 is here.
IND filing. Regulators review the safety package before human dosing. CT-G32 is targeting February 2027.
Phase 1. First doses in people, mainly to study safety and how the drug behaves in the body.
Phase 2. Dose-finding and early efficacy against placebo. UBT251 and retatrutide have published phase 2 results.
Phase 3. Large, long trials that support approval. Retatrutide's TRIUMPH program is here.
Regulatory review and approval. Tirzepatide and semaglutide are here.
Most drug candidates that enter human trials never reach approval. A rat result can't predict how much weight people will lose, which side effects they'll have, or what dose they'll need. The comparison with retatrutide was made in rats at matched molar doses. Retatrutide has human phase 2 and phase 3 data. CT-G32 has none.
No. CT-G32 has not been given to people, so there is no human dose, safety profile or legitimate product. Anything sold online under this name is not the sponsor's molecule. Treat any vendor listing as a red flag.
Following the Pipeline in PeptIQ
If you're on an approved GLP-1 or GIP/GLP-1 medicine, PeptIQ can log your doses, weight, waist and side effects so you and your clinician can see trends over time. As newer drugs like CT-G32 move through trials, a clean history of your own response gives you a baseline to discuss with your care team.
Frequently Asked Questions
Q: What is CT-G32?
A: CT-G32, also called SCO-940, is a preclinical obesity drug candidate from Scohia and Celltrion. It is designed to activate GLP-1, GIP, glucagon and amylin receptors.
Q: Has CT-G32 been tested in humans?
A: No. All reported data come from lab, rat and monkey studies. Celltrion plans to file a US IND by February 2027.
Q: Is CT-G32 better than retatrutide?
A: There is no way to know. The only comparison is a sponsor-reported rat study with no published numbers. Retatrutide has human trial data and CT-G32 does not.
Q: Is CT-G32 the same as CT632?
A: No. CT632 is the name of an editorial research website. CT-G32 is a drug candidate.
Q: What is a quadruple agonist?
A: A single molecule designed to activate four receptors. For CT-G32 those are GLP-1, GIP, glucagon and amylin.
This article is educational content from PeptIQ. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
